Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category.

The RECOVERY Trial has been awarded the 2021 Times Higher Education (THE) Award in the ‘Research Project of the Year: STEM’ category. The award was presented last night at a ceremony held at the Hilton London Metropole Hotel, and received by Oxford Population Health’s Director of Communications and Public Engagement, Anne Whitehouse.

Known as ‘the Oscars of higher education’, the awards attract hundreds of entries each year that ‘exemplify the talent, dedication and innovation of individuals and teams across all aspects of university life.’ This year, almost 600 entries were made across the 20 categories, demonstrating the important role universities have played in negotiating the challenges of the coronavirus pandemic to continue delivering impactful, innovative research. 

The ‘Research Project of the Year: STEM’ category, sponsored by Elsevier, is awarded to an individual or team at a UK or Irish higher education institution for ‘innovative research in STEM subjects that has a far-reaching impact and has caught, or has the potential to catch, the imagination of the public.’ Submissions needed to demonstrate evidence of significant or novel results, creative collaborations and imaginative communication of research results. 

Having launched as an emergency response in just nine days in March 2020, RECOVERY has found three effective treatments for COVID-19, discoveries that have vastly improved the care of patients hospitalised by coronavirus worldwide. These include the inexpensive steroid dexamethasone, the arthritis treatment tocilizumab and Ronapreve, a synthetic monoclonal antibody treatment that protects the immunocompromised. The study has also proved six other treatments to be ineffective against COVID-19 (including hydroxychloroquine and convalescent plasma), helping healthcare services to prioritise resources.

THE editor John Gill said: ‘The award winners demonstrate that 2019-20 was not just a year of pandemic disruption, it was also a year in which incredible achievements were made in all the areas you would hope and expect: world-changing research, brilliant learning and teaching, international and industrial engagement, and the full gamut of activities that run through universities like words through a stick of rock.’ 

Sir Martin Landray, Professor of Medicine and Epidemiology and Joint Chief Investigator for RECOVERY, said ‘This award is a real recognition that throughout this pandemic science has been our saviour. Understanding which treatments work and which do not has saved hundreds of thousands, probably millions of lives. Long-term investment into science, technology, and a real understanding of what matters to solve a pandemic has been at the heart of the success of RECOVERY.’

Sir Peter Horby, Professor of Emerging Infectious Diseases in the Nuffield Department of Medicine, University of Oxford, and Joint Chief Investigator for the RECOVERY trial, added: ‘This has really been a national effort that goes far beyond the team here at Oxford University, and we can't thank enough all the people who have made RECOVERY possible. We’d also like to thank our funders of course: UK Research and Innovation, the National Institute for Health Research (NIHR), Wellcome, and many other organisations who are supporting this work.’

The University of Oxford received two other awards. Professor Dame Sarah Gilbert, who developed the Oxford/AstraZeneca vaccine, received the THE Outstanding Achievement Award, with the judges crediting the marrying of her long-standing experience in immunology to “phenomenal foresight, perseverance and sheer hard work”.

The work of the University’s Public Affairs Directorate to make the university the go-to source of information for policymakers and the media during the pandemic delivered a third win for the institution on the night, in the Outstanding Marketing/Communications Team category.

The full list of the winners and details of the awards are available on the THE Awards website.

Similar stories

Global Research on AntiMicrobial resistance (GRAM) project

Antimicrobial resistance (AMR) is responsible for at least 1.27 million deaths per year — with over 97,000 deaths in 2019 in SE Asia alone, according to a study published in The Lancet by the Global Research on AntiMicrobial resistance (GRAM) project, who urged urgent action from policymakers and health communities to avoid further preventable deaths.

Cross-species vaccination by Professor George Warimwe

Royal Society 2021 Africa Prize lecture from Professor George Warimwe. More than 70% of emerging infectious diseases (including viruses) are zoonotic, meaning they are acquired from animals, with some causing serious illness and death in humans as well as the animal host. But, what if we could immunise both humans and animals with the same vaccine?

RECOVERY trial team members appointed MBEs

Two RECOVERY Trial team members have been recognised in the New Year Honours list 2022. RECOVERY Trial coordinator, Professor Richard Haynes, has been appointed Member of the Order of the British Empire (MBE) for services to Global Health, and Senior Clinical Trial Manager, Lucy Fletcher, has been appointed MBE for services to Clinical Trials. The New Year Honours list recognises outstanding achievements by a wide range of extraordinary people from across the United Kingdom. People are awarded honours for achievements in their field of work (including health, education, science and technology), as well as for making a difference to their community.

Susie, Phaik Yeong, Richard and Paul among new full Oxford professors!

In the 2021 Oxford Recognition of Distinction round, four MORU colleagues were awarded Full Professor title.

RECOVERY Trial launches in South Africa

The world’s largest clinical trial investigating treatments for COVID-19 has now launched in South Africa, with the first patient recruited today. This is the fifth country to take part in RECOVERY, joining Nepal, Indonesia, Vietnam, and the United Kingdom.

Antibiotic accountability: how countries and companies perform

Patients in north Africa and the Middle East are using antibiotics in sharply rising quantities far beyond the global average, raising concerns over the escalating risks of resistance to medicines to treat bacterial infections. Estimated antibiotic consumption for 204 countries between 2000 and 2018 shows a 46 per cent increase in global antibiotic usage, with a surge in nations including India and Vietnam.